All News
Understanding Non-arthritic Rheumatic iRAEs
A better understanding of rheumatic immune-related adverse event phenotypes beyond inflammatory arthritis has been furthered by work from three abstracts presented at EULAR 2019 in Madrid.
Read Article
Blinded by the Use of Antimalarials in Lupus?
Hydroxychloroquine (HCQ) will decrease SLE flares improve lipids, decrease clots, improve survival, augment the response to mycophenolate and are the cornerstone of treatment as per the SLE EULAR guidelines presented at EULAR 2019 in Madrid and also published in ARD.
Read Article
RheumNow Podcast from EULAR19 is up! EULAR 2019 Streamin' (6.14.19). You can view it here>> https://t.co/fTdH4kuCJX or listen on iTunes or SoundCloud >> https://t.co/TGxUixKoIj
Dr. John Cush RheumNow ( View Tweet)
RheumNow expanded twitter coverage of the #EULAR2019 annual meeting is sponsored by Horizon Pharma. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
#EULAR2019 commentary on RheumNow's meeting coverage site: https://t.co/5zpSSNXARC - hope you check it out. It features tweets, video interviews, articles and more. Our final meeting wrap up hits tomorrow. Hope everyone had safe travels home.
Dr. John Cush RheumNow ( View Tweet)
Eular highlights. Unanswered questions. Need RCTs in severe RA with targeted DMARD + biological? Should we cycle JAKs - need RCT. ?change target in RA to reflect real disease activity- inflammation and consider PROs separately #EULAR2019 @RheumNow
Janet Pope Janetbirdope ( View Tweet)
Eular highlights. Need to know if order of Rx of advanced therapies makes a long term difference in RA and PsA. ?better effectiveness or retention with one strategy vs another. ?too much drug cycling #EULAR2019 @RheumNow
Janet Pope Janetbirdope ( View Tweet)
Bad news. Chikungunya has arrived to Spain. The mosquito bites happened last May in Alicante.
Tres turistas islandeses en Alicante, primeros infectados de chikungunya en España https://t.co/v89dEVyFHr vía @el_pais
Emilio Martin Mola emartinmola ( View Tweet)
Interesting talks from @GeorgeTsokos. Response to Ustekinumab in #lupus trial was associated with reduction in IFN-gamma (IFN-II) but not IL17 (A & F), 22 or IFN-I signature (IFN-alpha) #EULAR2019 https://t.co/xZP4qjSUnH
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Major Unanswered Question: according to EULAR Recommendations a regular follow-up and monitoring of disease activity in patients with large vessels vasculitis is recommended
👉🏻But how often❓
👉🏻Is imaging useful at all❓
👉🏻How to screen for vessel stenosis & aneurysms❓#EULAR2019 https://t.co/xFvq1qfIGN
Juan Ovalles, MD, PhD DrJuanOvalles ( View Tweet)
Fibromyalgia Rx in EULAR guidelines includes amitryptylline which won the vote and duloxetine and neurontin or gabapentin which others chose. New thinking is to decide on Rx by type of pain. Don't forget exercise, sleep hygiene, CBT #EULAR2019 @RheumNow https://t.co/XEKG6WBU1i
Janet Pope Janetbirdope ( View Tweet)
Pts with RA have shame and guilt which correlates with demographics and disease activity. Something to think about, acknowledge and give proper help. FRI0030 #EULAR2019 @RheumNow
Janet Pope Janetbirdope ( View Tweet)
More in #gout news from #EULAR2019: men on uric acid-lowering therapy (and only 1/3 of people in this study were) were less likely to visit the #ER than those who weren’t
CreakyJoints.org CreakyJoints ( View Tweet)
Low dose steroids in RA are benign? I speak to @dr_rachelblack about cataract and glaucoma risk from steroids for @RheumNow (data from SAT0592 at #EULAR2019) https://t.co/3Qo4dZdTNK https://t.co/1kLQ2VwSD3
David Liew drdavidliew ( View Tweet)
BIIB059 is a monoclonal antibody that blocks BDCA2, which inhibits the production of inflammatory mediators in SLE. A Phase 1 trial showed drug to be safe& tolerable. It continues being investigated in SLE& cutaneous #lupus. #EULAR2019 #InsideLupusResearch https://t.co/bbcV3W57DD
Links:
Lupus Foundation of America · #LupusAwarenessMonth LupusOrg ( View Tweet)
Clinical Highlights #EULAR2019: Emapalumab, an IFN- gamma blocking monoclonal antibody, is effective in macrophage activation syndrome in patients with childhood-onset #SLE #PReS2019 @carmona_loreto >LA
ARD & RMD Open ARD_BMJ ( View Tweet)
We unfortunately missed out on it at #EULAR2019 but nice work and important paper from @CCalabreseDO @cappelliMD @MarieKostine @BetsyKirch @LCalabreseDO on PMR-like irAEs. An area worth exploring! https://t.co/IrEI7QzCPZ @RheumNow
David Liew drdavidliew ( View Tweet)
You can stop MTX in RA pts in low disease state after adding tofa 11 mg daily long acting for 24 Wks if CDAI <11 (Oral Shift) No diff btw continue vs D/C MTX. Some pts will be happy to stop MTX without loss of effect LBOOO4 #EULAR2019 @RheumNow
Janet Pope Janetbirdope ( View Tweet)
Sjogrens EULAR guidelines leave me dry! Lots of collaboration and work on guidelines but not much content which begs for RCTs in Sjogrens to help our pts. SP0190. But some recent RCTs recently + such as Leflunomide+ Hydroxychloroquine #EULAR2019 @RheumNow https://t.co/JZDcBLHai8
Janet Pope Janetbirdope ( View Tweet)
For PsA poly arthritis what do you usually start
Janet Pope Janetbirdope ( View Tweet)